@article{cdd491999185444491a18c827524c7c9,
title = "Combination treatments with immunotherapy in brain metastases patients",
abstract = "Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many advanced cancers. However, in most pivotal trials, patients with brain metastases (BM) were either excluded, or only selected patients were allowed. Therefore, there are still some concerns about the safety/efficacy ratio of ICI in patients with BM. In this special report we will provide an overview on the biological rationale for using ICI in the treatment of BM, the reported BM-related outcomes of clinical trials with a focus on ICI plus chemotherapy and ICI plus ICI combinations. Last, we will provide future challenges with this strategy, as well as directions for future research.",
keywords = "brain, neurologic, clinical trials, immunotherapy, lung, melanoma, skin, urologic, PEMBROLIZUMAB PEMBRO MONOTHERAPY, CELL LUNG-CANCER, CLINICAL-PRACTICE GUIDELINES, NIVOLUMAB PLUS IPILIMUMAB, OPEN-LABEL, SINGLE-ARM, MELANOMA, SURVIVAL, TUMORS, FOTEMUSTINE",
author = "Clemence Henon and Jordi Remon and {El Hendriks}, Lizza",
note = "Funding Information: No authors have financial disclosures relating to the current manuscript. J Remon has advisory role for Boehringer-Ingelheim, MSD, Pfizer, BMS, Astra-Zeneca; and received travel reimbursement from OSE immunotherapeutics, BMS, Astra-Zeneca. L Hen-driks has advisory role for Boehringer, BMS, Lilly, Roche, Pfizer, Takeda, MSD (all institution); received research funding from Roche, Boehringer Ingelheim, AstraZeneca (all institution); speaker for MSD; travel/conference reimbursement from Roche, BMS; mentorship program with key opinion leaders funded by AstraZeneca; fees for educational webinars funded by Quadia (self); interview sessions funded by Roche (institution). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd.",
year = "2020",
month = aug,
doi = "10.2217/fon-2020-0156",
language = "English",
volume = "16",
pages = "1691--1705",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "23",
}